How to Lose Weight With Insulin Resistance

Losing weight with insulin resistance can feel frustratingly difficult, but understanding why the condition makes fat loss harder is the first step towards an effective strategy. Insulin resistance causes the body to produce excess insulin, which actively promotes fat storage and suppresses the breakdown of stored fat for energy. This article explains the mechanisms behind this cycle, outlines the dietary patterns, exercise approaches, and medical options supported by UK guidance, and clarifies when to speak to your GP about assessment and support.

Why does insulin resistance make it harder to lose weight?

Chronically elevated insulin levels suppress lipolysis and promote fat storage, particularly visceral fat, creating a cycle that worsens insulin resistance and makes conventional calorie restriction less effective on its own.

Insulin resistance makes weight loss harder because the body must produce larger amounts of insulin to move glucose into cells, and chronically elevated insulin promotes fat storage rather than fat breakdown. Insulin is a hormone secreted by the pancreas in response to rising blood glucose. In a person with normal insulin sensitivity, relatively small amounts of insulin are sufficient to clear glucose from the bloodstream. When cells become resistant to insulin's signal, the pancreas compensates by releasing more, and these persistently high insulin levels actively suppress lipolysis, the process by which the body breaks down stored fat for energy.^[1][2]

This creates a cycle that can feel difficult to escape. Higher insulin levels encourage the liver to convert excess glucose into triglycerides, which are then stored in adipose tissue, particularly around the abdomen.^[2][3] Visceral fat, in turn, releases inflammatory signals that worsen insulin resistance further. Some research suggests that people with insulin resistance may experience stronger hunger signals and more pronounced cravings for carbohydrate-rich foods, partly because glucose is less efficiently taken up by muscle cells, though this remains an area of ongoing research.

Insulin resistance is closely associated with conditions including type 2 diabetes, polycystic ovary syndrome (PCOS), non-alcoholic fatty liver disease, and metabolic syndrome.^[23][24] It is not a diagnosis in itself under standard NHS criteria. In UK primary care, clinicians do not routinely measure insulin resistance directly; instead, they assess related markers such as HbA1c, fasting plasma glucose, or an oral glucose tolerance test (OGTT) to identify prediabetes or type 2 diabetes, alongside fasting lipids and blood pressure to build an overall picture of cardiometabolic risk. Fasting insulin and HOMA-IR calculations are not routinely offered on the NHS. Understanding the underlying mechanism is important because it explains why generic calorie-restriction advice, while still relevant, may need to be combined with specific dietary and lifestyle strategies to be effective in this group.

Which foods and eating patterns help with insulin resistance?

Replacing refined carbohydrates with wholegrains, increasing non-starchy vegetables, and limiting ultra-processed foods and added sugars reduces post-meal glucose spikes and lowers the insulin response required.

A diet that limits rapidly digested carbohydrates and prioritises fibre, protein, and healthy fats is associated with improved insulin sensitivity and supports weight loss in people with insulin resistance, in line with NHS Eatwell Guide principles and NICE guidance on reducing cardiovascular risk. The core principle is reducing the speed and magnitude of blood glucose rises after meals, which in turn lowers the insulin response required. This does not necessarily mean eliminating carbohydrates entirely, but rather choosing those with a lower glycaemic index and higher fibre content.

Practical dietary changes that evidence supports include:

• Replacing refined grains (white bread, white rice, processed cereals) with wholegrains such as oats, barley, and wholemeal bread

• Increasing non-starchy vegetables at each meal to add fibre and volume without a large glucose load

• Including adequate protein from sources such as fish, poultry, legumes, eggs, and low-fat dairy, as protein has a modest effect on satiety and a lower impact on blood glucose than carbohydrate

• Choosing unsaturated fats from olive oil, nuts, seeds, and oily fish, rather than saturated fats from processed foods

• Limiting ultra-processed foods and added sugars, including sugary drinks, which produce rapid glucose spikes

Eating patterns also matter beyond individual food choices. Time-restricted eating, where food intake is confined to a consistent window of around eight to ten hours per day, has shown promise in small studies for improving insulin sensitivity, though larger long-term trials are still needed.^[6][7] Before attempting time-restricted eating or any form of fasting, people who are pregnant or breastfeeding, those with a history of eating disorders, and those taking glucose-lowering medicines that can cause hypoglycaemia (such as insulin or sulfonylureas) should seek advice from their GP or diabetes team first, as fasting may not be appropriate or may require medication adjustment.

The Mediterranean dietary pattern, which NICE references in its guidance on cardiovascular risk reduction and lipid modification, aligns well with these principles and has a strong evidence base.^[4] Portion awareness remains relevant, as overall energy intake still influences weight, even when food quality improves.

How much does exercise help, and what type is best?

Both aerobic exercise and resistance training improve insulin sensitivity through complementary mechanisms; combining them offers greater benefit than either alone, and even breaking up prolonged sitting reduces postprandial glucose.

Regular physical activity meaningfully improves insulin sensitivity, and both aerobic exercise and resistance training have distinct, complementary benefits for people with insulin resistance. Exercise works partly by activating glucose uptake in muscle cells through a pathway that does not require insulin, meaning that physical activity can lower blood glucose and reduce the insulin burden even when cells are resistant to the hormone's normal signal.^[15][16] This effect is acute, lasting for several hours after a session, and also cumulative, improving baseline insulin sensitivity over weeks and months of consistent training.

Aerobic exercise, such as brisk walking, cycling, swimming, or jogging, is effective at reducing visceral fat and improving cardiovascular markers that often accompany insulin resistance. The UK Chief Medical Officers' Physical Activity Guidelines, reflected in NHS guidance, recommend at least 150 minutes of moderate-intensity aerobic activity per week for adults, alongside muscle-strengthening activity on at least two days per week, and this is a reasonable starting point.^[9][10] Resistance training, including bodyweight exercises, free weights, or resistance bands, builds skeletal muscle mass, and muscle is the body's primary site of glucose disposal. More muscle means a greater capacity to absorb glucose after meals, reducing the insulin response required.

Combining both forms of exercise appears to offer greater benefit than either alone. For people who are currently sedentary, even modest increases in daily movement, such as breaking up prolonged sitting with short walks, have been shown to reduce postprandial glucose levels.^[12][13] Practical suggestions include:

• Aiming for at least two resistance sessions per week targeting major muscle groups

• Incorporating incidental activity such as taking stairs or walking rather than driving for short journeys

• Starting gradually to reduce injury risk, particularly if there are existing joint or cardiovascular concerns

People who use insulin or sulfonylureas should seek advice from their GP or diabetes team before significantly increasing their activity levels, as unaccustomed exercise can increase the risk of hypoglycaemia and may require adjustments to food intake, timing, or medication. Speaking to a GP or physiotherapist before starting a new exercise programme is advisable if there are any other underlying health conditions.

Can medication or medical support help you lose weight?

GLP-1 receptor agonists including semaglutide and tirzepatide are MHRA-authorised for weight management in the UK and can support loss alongside lifestyle changes, subject to individual clinical eligibility.

Several medicines are available in the UK that can support weight loss in people with insulin resistance, and access to structured medical support significantly improves outcomes compared with lifestyle changes alone. Medication is considered alongside, not instead of, dietary and activity changes, and eligibility depends on individual clinical assessment.

GLP-1 receptor agonists are the most widely discussed class of medicines in this context. Semaglutide is available in the UK as Wegovy (licensed for chronic weight management, with a maintenance dose of 2.4 mg weekly and a higher dose option of 7.2 mg weekly within the licensed regimen) and as Ozempic (licensed for type 2 diabetes). Liraglutide is available as Saxenda for weight management. These medicines work by mimicking the gut hormone GLP-1, which stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and reduces appetite.^[23][24] Tirzepatide (Mounjaro) is authorised by the MHRA both for type 2 diabetes and for chronic weight management; it acts on both GLP-1 and GIP receptors.^[21][22] Orforglipron (Foundayo) is a further oral option that has received a UK licence for chronic weight management.^[20] Orlistat remains a licensed option for obesity management. This list reflects medicines with a UK marketing authorisation at the time of writing but is not exhaustive, and the options available to any individual depend on their clinical circumstances.

NICE technology appraisals set out the criteria under which these medicines may be recommended for NHS use, and local Integrated Care Boards (ICBs) make commissioning decisions about which treatments are available in their area. Metformin, while not licensed specifically for weight loss, is widely used in type 2 diabetes and PCOS and may modestly improve insulin sensitivity.

These medicines are not suitable for everyone. They are not recommended during pregnancy or breastfeeding. People with a personal or family history of certain thyroid conditions or pancreatitis, and those with other relevant medical history, should discuss suitability with their prescriber. If you experience severe or persistent abdominal pain while taking any of these medicines, seek medical attention promptly as this may be a sign of pancreatitis. People with type 2 diabetes who have existing eye complications should discuss this with their prescriber before starting treatment, as rapid changes in blood glucose control can affect the eyes in some individuals. If you suspect you are experiencing a side effect from a prescribed medicine, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Mounjaro is one option a prescriber may consider after an online consultation with Bolt Pharmacy, a GPhC-registered UK online pharmacy, and is only prescribed where it is clinically appropriate.

Structured weight management programmes, referral to a dietitian, and NHS Tier 3 or Tier 4 services are also available pathways depending on clinical need and local provision. A GP can advise on which options are appropriate and accessible locally.

When should you speak to your GP about insulin resistance?

Speak to your GP if you have unexplained difficulty losing weight, symptoms suggesting poor glucose control, a family history of type 2 diabetes, or signs such as acanthosis nigricans, as these warrant metabolic assessment.

You should speak to your GP about insulin resistance if you have symptoms or risk factors that suggest your blood glucose regulation may be impaired, particularly if lifestyle changes have not produced the expected results. Insulin resistance is not routinely tested for in isolation on the NHS. A GP can assess related markers including HbA1c, fasting plasma glucose, fasting lipids, and blood pressure, which together give a picture of metabolic health and cardiometabolic risk. An oral glucose tolerance test (OGTT) may also be used in some circumstances. A formal diagnosis of prediabetes or type 2 diabetes, or a condition strongly associated with insulin resistance such as PCOS or non-alcoholic fatty liver disease, is a clear prompt to seek assessment and support.

Signs that warrant a GP appointment include:

• Unexplained difficulty losing weight despite consistent dietary and activity changes

• Persistent fatigue, increased thirst, or frequent urination, which may suggest blood glucose is poorly controlled

• A family history of type 2 diabetes combined with a BMI above the threshold relevant to your ethnic background (NICE guidance notes that South Asian, Chinese, and other high-risk groups may develop metabolic complications at lower BMI values than the standard thresholds)^[26][27]

• Irregular menstrual cycles or signs of PCOS in women of reproductive age

• Darkened, velvety skin patches (acanthosis nigricans), particularly around the neck or armpits, which can be a visible sign of high insulin levels

If you are already taking medication for a related condition and your weight is not responding, or if you are experiencing side effects that are affecting your ability to maintain lifestyle changes, your GP can review your management plan and consider referral or additional support. An NHS Health Check, available to adults aged 40 to 74 in England who are not already being managed for a relevant condition, can also identify early signs of metabolic risk.^[28] Contact NHS 111 if you develop symptoms that concern you urgently but are not life-threatening, and call 999 or go to A&E only in a genuine emergency.

Scientific References

1. Is glutamate an adipose redox signal that regulates lipolysis?.
2. Why hyperinsulinemia is detrimental to weight loss: insights from type 1 diabetes.
3. Lipolysis in Health and Disease: Pathways, Regulation, and Metabolic Consequences.
4. Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238).
5. Type 2 diabetes: prevention in people at high risk – Recommendations (PH38).
6. Effect of Time-Restricted Eating on Weight Loss in Adults with Type 2 Diabetes.
7. Effects of time-restricted eating on markers of glucose metabolism and regulation in individuals with prediabetes or type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.
8. The Effects of Time-Restricted Eating in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.
9. Physical activity guidelines: UK Chief Medical Officers' report.
10. UK Chief Medical Officers' physical activity guidelines (full guidance text).
11. Physical activity guidelines for adults aged 19 to 64.
12. Acute Effects of Interrupting Prolonged Sitting on Glucose, Insulin and Lipid Metabolism in Healthy Populations: A Three-Level Meta-Analysis.
13. Acute effects of interrupting prolonged sitting with short bouts of physical activity on postprandial metabolism in sedentary adults: A multi-level meta-analysis.
14. Acute effects of 'exercise snacks' on postprandial glucose and insulin responses in populations at metabolic risk: a meta-analysis with exploratory meta-regression and vascular outcomes.
15. Prior AICAR stimulation increases insulin sensitivity in mouse skeletal muscle in an AMPK-dependent manner.
16. Role of oxidative stress in impaired insulin signaling associated with exercise-induced muscle damage.
17. Canonical and Alternative Pathways (Insulin and Exercise) of GLUT4 Synthesis, Signaling, Intracellular Clustering, and Recruitment to the Plasma Membrane.
18. Exercise regulation of glucose transport in skeletal muscle.
19. Single-dose 7.2 mg semaglutide (Wegovy) pen approved to treat adult patients with obesity.
20. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes.
21. GLP-1 medicines for weight loss and diabetes: what you need to know.
22. Tirzepatide – BNF drug monograph.
23. The multifaceted role of GLP-1 in metabolic disorders, chronic inflammation, and aging: Mechanisms and therapeutic potential.
24. GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications.
25. Diabetic retinopathy: management and monitoring (NG242) – effectiveness of intensive treatments to lower blood glucose levels.
26. Type 2 diabetes in adults: quality standard (QS167) – referring people at high risk.
27. Appendix A1: Summary of evidence from surveillance (NG246) – lower BMI thresholds for South Asian and Chinese populations.
28. NHS Health Check.

Frequently Asked Questions